Gilgamesh Ventures Closes Second Fund At $35 Million With Backing From Institutional Investors

Gilgamesh Ventures, a New York City-based fintech-focused venture capital firm co-founded by Miguel Armaza, a fintech podcaster and former banker, and fintech entrepreneur Andrew Endicott, has closed its second fund, bringing its total assets under management to $35 million. The new fund attracted institutional backers including Foundation Capital, GBM Ventures, and Encore Bank, as well as prominent fintech founders like Renaud Laplanche and Dan Henry. Since launching in 2021, Gilgamesh has backed 44 companies across 10+ markets, and its debut fund already delivered a 39% net IRR. HQ: #NewYork #NY #NewYorkCity #NYC #VentureCapital #GilgameshVentures #MiguelArmaza #AndrewEndicott #TradedVC

More Deals

View All

Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts. FOUNDERS: Ben Lamm & George Church TARGET VALUATION: $23,000,000,000 HQ: Dallas, Texas #VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC